I. W. Schiller, F. C. Lowell
1956
Citations
0
Influential Citations
2
Citations
Quality indicators
Journal
The Journal of allergy
Abstract
Abstract 1.1. Buclizine, 1-p-chlorbenzhydryl-4-p-tertiary butylbenzylpiperazine dihydrochloride, a new antihistaminic drug, was administered in seventy patients with allergic and related states, with the majority of these patients under observation for many months. 2.2. Buclizine, taken orally in doses of 25 to 75 mg. daily for an average of four months, produced no significant abnormalities in the formed blood elements or in hepatic and renal function. 3.3. In contrast to the prolonged activity of the drug in guinea pigs, the duration of action of comparable dosage in man in relatively short—a point deserving further study. 4.4. The drug appeared to be effective is relieving the symptoms in the majority of patients with perennial allergic rhinitis, vasomotor rhinitis, and urticaria.